Coker, Jessica L.
Tripathi, Shanti P.
Knight, Bettina T.
Pennell, Page B.
Magann, Everett F
Newport, D. Jeffrey
Stowe, Zachary N.
Funding for this research was provided by:
National Institute on Drug Abuse (UL1TR000039)
National Institutes of Health (TRCBS P50 MH-77928, SCOR P50 MH 68036)
Article History
Received: 27 January 2017
Accepted: 14 June 2017
First Online: 30 June 2017
Compliance with ethical standards
:
: This study was funded by a grant from the NIH (TRCBS P50 MH-77928, SCOR P50 MH 68036). The first author also received support from the UAMS NIDA T32 grant (UL1TR000039).
: The original study was approved by the Emory University Institutional Review Board (IRB) on July 11, 2007 (no. 4249).
: Informed consent was obtained from all individual participants included in the study.
: Drs. Coker and Magann and Mr. Tripathi have no conflicts of interest.Dr. Pennell has received research support from the National Institutes of Health (NIH), the Epilepsy Foundation, and the Epilepsy Therapy Project, and speaker’s honoraria from the American Academy of Neurology, the American Epilepsy Society, the India Academy of Neurology, and the University of Maryland.Dr. Newport has received research support from NARSAD and the National Institutes of Health (NIH), as well as Eli Lilly, GlaxoSmithKline (GSK), Janssen, and Wyeth Corporations, and speaker’s honoraria from Astra-Zeneca Pharmaceuticals (AZP), Eli Lilly, GSK, and Pfizer CorporationsDr. Stowe has received research support from NIH, SAGE Therapeutics, and Janssen; consulted to GlaxoSmithKline, Pfizer, and Wyeth Corporations; and received speakers’ honoraria from the GlaxoSmithKline, Pfizer, Wyeth, Eli Lilly and Forest Corporations.Ms. Knight’s adult son is employed by GlaxoSmithKline and has stock options as part of his employment.No other coauthor or any family member holds equity positions in pharmaceutical or biomedical corporations.